March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
March 20th 2023
Multidisciplinary Management of Breast Cancer Brain Metastases
This review summarizes the most up-to-date approach to the multidisciplinary management of patients with breast cancer brain metastases.
Breast Cancer Brain Metastasis: An Ongoing Clinical Challenge and Opportunity for InnovationOctober 15th 2016
Brain metastasis remains a relatively common and particularly devastating complication of breast cancer and has proven a particularly challenging area for therapeutic innovation.
Radiomics Identifies Which Glioblastoma Patients Would Benefit From BevacizumabOctober 10th 2016
A new study is suggesting that radiomic features subjected to machine learning algorithms may be able to identify imaging signatures that defined a subset of patients with recurrent glioblastoma who may gain the most benefit from antiangiogenic therapy.
Markers Could Improve Treatment Stratification for Pediatric MedulloblastomaOctober 3rd 2016
The use of an intensified treatment regimen to treat metastatic medulloblastoma in children and adolescents conferred an overall favorable survival, according to the results of a recent study. However, patients within varying subgroups and with certain biologic parameters did not have uniform outcomes.
Adjuvant Temozolomide Improves Survival in Some Anaplastic Gliomas PatientsJune 3rd 2016
Adjuvant temozolomide chemotherapy following radiotherapy improves survival among patients with anaplastic gliomas that do not harbor 1p/19q co-deletions, according to interim results from a phase III trial.
Polio-Rhinovirus Conjugate Receives Breakthrough Therapy Designation for GlioblastomaMay 20th 2016
The US Food and Drug Administration granted the “breakthrough therapy” designation to a recombination poliovirus/rhinovirus conjugate known as PVS-RIPO, for treatment of recurrent glioblastoma multiforme.
Applications of Genomic Sequencing in Pediatric CNS TumorsMay 15th 2016
This review will discuss examples of clinical applications of tumor and germline genomic testing for children with central nervous system (CNS) tumors, as well as promising investigative strategies.
Pediatric Neuro-Oncology: Time to Go MolecularMay 15th 2016
One recurring theme from genomic studies of pediatric CNS tumors (and almost all cancers, for that matter) is that tumors that historically appeared to be a single entity based on examination under the microscope and routine immunohistochemical staining actually harbor molecularly distinct subgroups when analyzed by genomic sequencing techniques.
Gamma Knife Radiosurgery for 5 to 10 Brain Metastases: A Good Option for Upfront TreatmentApril 15th 2016
The aggressive management of brain metastases with SRS has supplanted radiation therapy in an effort to maintain patient quality of life in an era of advancing systemic cancer options.
Gamma Knife Radiosurgery for 5 to 10 Brain Metastases: May Not Be Reasonable as Sole Upfront TreatmentApril 15th 2016
Until prospective randomized clinical data accrue and mature, this controversial issue will continue to suffer from overinterpretation of inadequate supporting data.
Chemotherapy After Radiation Increases Survival for Low-Grade Glioma PatientsApril 13th 2016
The combination of chemotherapy and radiation therapy resulted in longer overall survival than radiation alone in certain patients with grade 2 gliomas, according to long-term results from a randomized trial.
Vaccine Therapy, Oncolytic Viruses, and GliomasMarch 16th 2016
In this article, we will discuss some of the vaccination and oncolytic virus strategies being evaluated in the clinic for malignant gliomas. The vaccines reviewed here include the cell-based and the non–cell-based.
Vaccine Therapies Against Gliomas: Prime Time Yet?March 15th 2016
The promise of vaccine-based anticancer therapies has been explored for a number of years. However, the research met with little success in its early phases, largely because of a poor understanding of the biology of the immune system and its role in combatting cancer.
Innovative GBM Trial Could Hasten Development of New TreatmentsNovember 24th 2015
Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.